

ASX Announcement

Race Strengthens Board

- **Dr Megan Baldwin appointed as Independent Non-Executive Director**
- **25+ years in biotech industry, including extensive experience in cancer therapies**
- **Video interview with Dr Baldwin discussing her appointment is available via this link:**
<https://announcements.raceoncology.com/link/OPQvqy>

18 December 2024 – Race Oncology Limited (“Race”) is pleased to announce the appointment of experienced biotechnology executive, Dr Megan Baldwin, to its board as an Independent Non-Executive Director, effective 1 January 2025.

Dr Baldwin has more than 25 years of experience working on therapeutic drug development programs for oncology and ophthalmic indications. She is the Founder and Chief Innovation Officer of Opthea Limited (ASX:OPT; NASDAQ:OPT), a late-stage biopharmaceutical company developing a novel therapy to address the unmet need in the treatment of retinal eye diseases. Her experience includes 10 years as CEO and Managing Director of Opthea, where the company’s lead asset was advanced through preclinical studies to global Phase 3 registrational trials. Dr Baldwin also has extensive capital raising experience, including the completion of an A\$180 million initial public offering (IPO) and listing on the US Nasdaq exchange. Prior to Opthea, Dr Baldwin was previously employed at Genentech (now Roche) as a researcher before moving to Genentech’s commercial division.

Dr Baldwin’s experience in oncology drug development includes both preclinical and clinical investigation of inhibitors targeting angiogenic factors involved in tumour growth and spread, as well as management of competitive intelligence activities to support Genentech’s early stage oncology programs.

Dr Baldwin has extensive corporate governance experience and currently serves on the boards of Anaxis Pharma and Gertrude Biomedical, and is a director of Ausbiotech. She holds a PhD in Medicine from the University of Melbourne, having conducted her doctoral studies at the Ludwig Institute for Cancer Research.

Race’s Executive Chair, Dr Pete Smith commented, “We are delighted to welcome Dr Megan Baldwin to our board as an Independent Non-Executive Director. She brings to the role an exceptional depth of experience in biotechnology and therapeutic drug development. Megan’s leadership at Opthea, steering the company through its global Phase 3 trials, reflects her visionary approach to addressing critical unmet medical needs. We look forward to leveraging her expertise and insights to help drive the future success of Race.”

Video interview

Investors are invited to view a video interview with Dr Megan Baldwin discussing her appointment to the Race Oncology board, via the following link: <https://announcements.raceoncology.com/link/OPQvqy>

-ENDS-



About Race Oncology (ASX: RAC)

Race's lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin.

Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anti-cancer activity in solid tumours. Race is also exploring RC220 bisantrene as a low intensity treatment for acute myeloid leukaemia.

Race is investigating the effect of bisantrene on the m⁶A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of the m⁶A RNA pathway has been described in numerous peer reviewed studies as a driver of a diverse range of cancers.

Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at www.raceoncology.com.

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Peter Smith, Chair
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au